Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 3763 3783 3792
This examiner grants 78% of resolved cases
Theodore J. Stigell is a patent examiner in Tech Center 3700 and Art Unit 3763. He has a substantial record of 1275 resolved cases. The examiner maintains an allowance rate of 78.3 percent, which indicates that a large majority of applications reach issuance. This percentage suggests that the examination process in this unit frequently results in a grant for the applicant.
The median time to allowance is 1180 days. This timeframe provides a clear expectation for the duration of the prosecution cycle, showing that successful applications reach issuance within this median period. This duration is a key characteristic of the examiner's historical data and is an important consideration for practitioners managing patent portfolios in Tech Center 3700.
The data also shows an interview lift of 14.9 percent. This metric indicates that the probability of allowance increases when an interview is conducted, even with a base allowance rate of 78.3 percent. With 1275 resolved cases, these figures represent a stable set of outcomes for practitioners. The combination of the allowance rate and the median days to allowance defines the typical experience for applicants in Art Unit 3763.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18323756 | ROBOTIC DRIVE SYSTEM FOR FACILITATING TREATMENTS OF THE NEUROVASCULATURE AND METHODS OF USE | Non-Final OA | Route 92 Medical, Inc. |
| 18653276 | MEDICAL DEVICES AND RELATED METHODS FOR CONTROLLING AND/OR LOCKING A NEEDLE | Non-Final OA | Boston Scientific Scimed, Inc. |
| 17970816 | SYSTEMS AND METHODS FOR PRODUCING MIXTURES | Final Rejection | Boston Scientific Scimed, Inc. |
| 17567620 | IMPLANTATION NEEDLE FOR INSERTING A SUBCUTANEOUSLY INSERTABLE ELEMENT INTO A BODY TISSUE | Non-Final OA | Roche Diabetes Care, Inc. |
| 18173673 | POINT OF CARE DRUG DELIVERY APPARATUS AND METHOD | Final Rejection | Genentech, Inc. |
| 18837186 | DYNAMICALLY RIGIDIZING COMPOSITE MEDICAL STRUCTURES | Non-Final OA | Neptune Medical Inc. |
| 18588540 | SYSTEMS AND METHODS FOR DETECTING FLUID INFILTRATION | Non-Final OA | Welch Allyn, Inc. |
| 18344494 | AUTO-INJECTOR AND RELATED METHODS OF USE | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18390785 | Control of Irrigation in a Phacoemulsification System | Final Rejection | JOHNSON & JOHNSON SURGICAL VISION, INC. |
| 18168275 | FLEXIBLE RADIOPAQUE CATHETER SHAFT | Final Rejection | Medtronic, Inc. |
| 18726745 | SYSTEMS AND METHODS FOR IRRIGATING AN ANATOMIC SPACE | Non-Final OA | The General Hospital Corporation |
| 18539290 | RESIN-COATED WIRE AND DRUG SOLUTION INJECTION DEVICE | Final Rejection | Asahi Intecc Co., Ltd. |
| 18772862 | Connector Assembly | Non-Final OA | Becton, Dickinson and Company |
| 18890386 | CATHETER ASSEMBLY | Non-Final OA | TERUMO KABUSHIKI KAISHA |
| 18347672 | MEDICAL DEVICE | Non-Final OA | TERUMO KABUSHIKI KAISHA |
| 18345812 | MALE CONNECTOR AND MEDICAL DEVICE | Non-Final OA | Terumo Kabushiki Kaisha |
| 18245191 | Minimally Invasive and Semi-Automated Myocardial Injection Device | Final Rejection | University of South Carolina |
| 19211805 | ON-BODY INTERLOCK FOR DRUG DELIVERY DEVICE | Non-Final OA | INSULET CORPORATION |
| 18694103 | GLUCOSE MONITOR INJECTION PORT | Final Rejection | INSULET CORPORATION |
| 18497431 | APPARATUS AND METHOD FOR CONTROLLING INJECTION OF DRUG INTO OBJECT, AND RECORDING MEDIUM STORING COMPUTER PROGRAM FOR PERFORMING THE METHOD | Non-Final OA | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) |
| 18687942 | Activation member and subassembly for a medicament delivery device | Non-Final OA | SHL Medical AG |
| 18302160 | NEEDLE-FREE INJECTOR | Final Rejection | JEISYS MEDICAL INC. |
| 18687754 | Mechanical Clamshell Cathlock | Non-Final OA | Bard Peripheral Vascular, Inc. |
| 18709360 | PERITONEAL DIALYSIS SYSTEM HAVING A CAPILLARY PATIENT LINE FILTER | Non-Final OA | BAXTER HEALTHCARE SA |
| 17795341 | WINGED CAPSULE | Final Rejection | Elanco Tiergesundheit AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy